REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Dec 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-12-10

Reporting Person: Landry Robert E (EVP Finance CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-10	Common Stock	M	1500	$555.67	Acquired	31457	Direct
2021-12-10	Common Stock	F	1384	$664.34	Disposed	30073	Direct
2021-12-11	Common Stock	F	697	$664.34	Disposed	29376	Direct
2021-12-13	Common Stock	S	116	$662.5	Disposed	29260	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-10	Non-Qualified Stock Option (right to buy)	$555.67	M	1500	Disposed	2025-12-16	Common Stock (1500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	229	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: The stock option award vests in four equal annual installments, commencing one year after the date of grant.